\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
Unit dedicated to Altamira’s activities in fitness products for clients
OTC Consumer Health will be led by Jean Lachance, an experienced marketing strategist
HAMILTON, BERMUDA / ACCESSWIRE / February 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company committed to creating healing products that address significant unmet medical needs, today announced the creation of a new business unit, OTC Consumer Health, to the ongoing global launch of Bentrio™, its nasal spray for coverage against viruses and airborne allergens.
OTC Consumer Health will be led by Jean Lachance, who will join Altamira in May 2022. Mr. Lachance brings more than 20 years of global experience in marketing and selling pharmaceutical and fitness products to over-the-counter (“OTC”) customers. Categories “Allergies”, to which Bentrio™ belongs.
Mr. Lachance recently oversees global marketing projects for a variety of customer care products at Abbott EDP (Established Products Division). Previously, he held the position of Senior Regional Director of Marketing for Europe at Mundipharma Consumer Care; Marketing Director of Merck Consumer Care (now Bayer Consumer Care); Allergy Brand Manager
“We are excited to welcome Jean as a new member of our control team,” said Thomas Meyer, founder, president and CEO of Altamira Therapeutics. In the Allergy and Cough and Cold categories, Jean is exceptionally well rated to maximise the global opportunity we see for Bentrio, which will drive strong expansion in 2022 and beyond. “
About Altamira Therapeutics
Altamira Therapeutics is committed to developing healing products that address significant unmet medical needs. Lately, the company is active in 3 areas: the progression of RNA cures for extrahepatic healing targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for coverage against airborne viruses and allergens (Bentrio™; commercial) or the vertigo remedy (AM-125; Phase 2), and progression of cures for the intratympanic remedy of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3) The company was founded in 2003 and is headquartered in Hamilton, Bermuda, and its main operations are located in Basel, Switzerland.
Forward-Looking Statements
This press release would possibly include statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements that are not forward-looking statements. in fact. statements and would possibly come with statements that deal with the long-term operational, monetary or business manner or methods or expectations of Altamira Therapeutics. In some cases, you can identify such statements by forward-looking words such as “possibly”, “may also just”, “will”, “deserve”, “expect”, “plan”, “anticipate”, “believe”. “, “estimates”, “predicts”, “plans”, “potential”, “outlook” or “continues”, or the negative form of those terms or any other comparable terminology. Forward-looking statements are based on the expectations and ideals of control and involve significant dangers and uncertainties that may also cause actual effects, progressions and business decisions to differ materially from those considered through such statements. These dangers and uncertainties come with, but are not limited to, the approval and timing of the commercialization of Bentrio(TM) (AM-301), Altamira Therapeutics’ desire and ability to offload a really large additional budget to track the progression of its product candidates, the timing and conduct of prestigious clinical trials of the products Altamira Therapeutics product candidates, the clinical application of Altamira Therapeutics product candidates, the timing or likelihood of presentations, s and regulatory approvals, the intellectual asset position of Altamira Therapeutics, and the financial condition of Altamira Therapeutics, adding the effect of any long-term acquisitions, divestitures, partnerships, licensing transactions, or adjustments in Altamira Therapeutics’ design capital, adding offerings of long-term securities. These dangers and uncertainties also come with, but are not limited to, those described under “Risk Factors” in Altamira Therapeutics’ Annual Report on Form 20-F for the fiscal year ended December 31, 2020 and elsewhere. presented through Altamira. SEC Therapeutics, which can be obtained free of charge from the Securities and Exchange Commission’s online page at: www. sec. gov. If one or more of these hazards or uncertainties were to materialize, or if the underlying assumptions were to prove incorrect, actual effects could potentially vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to such dangers and uncertainties. You deserve not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics assumes no legal responsibility to update them based on new forms, long-term progressions or otherwise, except as required by applicable law. required.
Contact for investors:
Stephen Kilmer(647) 872-4849sjk@altamiratherapeutics. com
SOURCE: Altamira Therapeutics Ltd.
See the edition in accesswire. com: https://www. accesswire. com/687293/Altamira-Therapeutics-Establishes-OTC-Consumer-Health-Business-Unit